Last updated: February 9, 2026
Case Overview
AbbVie Inc. filed suit against Hetero USA Inc. on August 13, 2015, in the U.S. District Court for the District of Delaware. The dispute centers on patent infringement concerning AbbVie’s Humira (adalimumab), a blockbuster biologic therapy used in autoimmune diseases. AbbVie asserts that Hetero’s biosimilar product infringes on several patents protecting Humira’s formulation and manufacturing process.
Legal Claims
AbbVie claims infringement of U.S. Patent Nos. 8,916,157; 9,073,987; and 9,071,378, covering aspects of the antibody’s structure, methods of manufacturing, and stability. The company seeks injunctive relief, damages, and a court declaration barring Hetero from launching its biosimilar until patent expiry.
Procedural Timeline
- Complaint Filed: August 2015
- Initial Dispute Focus: Patent infringement and potential preliminary injunction
- Key Motions: Various motions to dismiss and for summary judgment
- Settlement Discussions: Ongoing, undisclosed at the latest update
- Current Status: Case remains active with ongoing discovery and pretrial proceedings
Patent and Regulatory Context
- Patent Lifespan: The patents involved extend into the late 2020s and early 2030s, potentially blocking biosimilar entry until their expiration.
- FDA Exclusivity: Humira received orphan drug designation, securing seven years of exclusivity for some indications, but biosimilar entry in the U.S. is primarily governed by patent rights, not exclusivity periods.
- Biosimilar Market Dynamics: Hetero’s challenge reflects broader industry efforts to introduce biosimilars for blockbuster biologics. The case exemplifies patent litigation strategies aimed at delaying biosimilar proliferation.
Legal Challenges and Strategy
AbbVie’s defense hinges on patent validity and infringement, insisting that Hetero’s biosimilar infringes core claims and that patents are non-obvious and properly issued. Hetero’s defense likely challenges patent validity under Section 101 (patent eligibility), Section 102/103 (novelty and non-obviousness), and may question infringement allegations.
Implications for Industry
AbbVie’s litigation underscores the importance of robust patent portfolios to protect biologic innovations. The outcome influences biosimilar entry timing, impacting market share and pricing dynamics. Early stage litigation often results in settlement agreements or delayed market entry for biosimilar manufacturers.
Recent Developments
As of the latest records, no final judgment or settlement has been announced. The case is progressing through discovery, with Hetero contesting the patent claims' validity and infringement. The court’s decisions on motions to dismiss or for summary judgment will substantially influence the case trajectory.
Analysis
- Patent Strength: AbbVie's patent estate for Humira is extensive, covering numerous formulations and manufacturing processes, making litigation protracted and complex.
- Market Impact: Potential delay of Hetero’s biosimilar reduces market competition for Humira, extending AbbVie’s market exclusivity.
- Legal Environment: The case exemplifies the strategic use of patent litigation in the biologics space, where innovations are heavily protected by patent rights, and biosimilar entry depends on litigation outcomes.
Key Takeaways
- The case exemplifies the ongoing patent litigation landscape for biologics.
- Patent validity and infringement claims are central to determining biosimilar market access.
- Outcomes influence not only AbbVie's market dominance but also biosimilar market development.
- The case highlights the complexity of biologic patent protection, requiring deep biological and legal expertise.
- Litigation prolongs biosimilar entry, impacting healthcare costs and patient access.
FAQs
1. What are the main patents involved in AbbVie’s litigation against Hetero?
The patents include Nos. 8,916,157; 9,073,987; and 9,071,378, covering structural features and manufacturing methods of Humira.
2. How does patent litigation affect biosimilar market entry?
Litigation can delay biosimilar approval and market launch, as courts may prohibit infringing products until patents expire or are invalidated.
3. What defenses might Hetero use against AbbVie’s claims?
Hetero may challenge the patents' validity through arguments of non-obviousness, lack of novelty, or patent ineligibility under 35 U.S.C. §§ 101-103.
4. How does the case impact AbbVie’s competitive position?
A favorable ruling maintains exclusivity, delaying biosimilar competition and preserving market share and revenues.
5. What is the broader significance of this case?
It illustrates the strategic role of patent litigation in the biologics sector and the lengths companies go to extend market exclusivity for blockbuster drugs.
Sources
- U.S. District Court for the District of Delaware, Case No. 1:15-cv-00889.
- U.S. Patent and Trademark Office databases.
- Industry reports on biosimilar litigation.
- AbbVie press releases and legal filings.
- Market analysis reports on biologics and biosimilars.
